WHO stops hydroxychloroquine trials over safety concerns

World Health Organization said Monday it was halting testing of the drug for COVID-19 after studies questioned its safety, including one published Friday that found it actually increased the risk of death. (File/AFP)
Short Url
Updated 26 May 2020

WHO stops hydroxychloroquine trials over safety concerns

  • Trump has led the push for hydroxychloroquine as a potential shield or treatment for the virus
  • Brazil’s health ministry said it would keep recommending hydroxychloroquine for COVID-19

GENEVA: The WHO suspended trials of the drug that Donald Trump has promoted as a coronavirus defense, fueling concerns about the US president’s handling of the pandemic that has killed nearly 100,000 Americans.
Trump has led the push for hydroxychloroquine as a potential shield or treatment for the virus, which has infected nearly 5.5 million people and killed 345,000 around the world, saying he took a course of the drug as a preventative measure.
Brazilian President Jair Bolsonaro has also heavily promoted hydroxychloroquine while the virus has exploded across nation, which this week became the second most infected in the world after the United States.
But the World Health Organization said Monday it was halting testing of the drug for COVID-19 after studies questioned its safety, including one published Friday that found it actually increased the risk of death.
The WHO “has implemented a temporary pause... while the safety data is reviewed,” its chief Tedros Adhanom Ghebreyesus said, referring to the hydroxychloroquine arm of a global trial of various possible treatments.
Trump announced last week he was taking the drug, explaining he had decided to take after receiving letters from a doctor and other people advocating it.
“I think it’s good. I’ve heard a lot of good stories,” Trump told reporters then, as he declared it safe.
Trump dismissed the opinions then of his own government’s experts who had warned of the serious risks associated with hydroxychloroquine, with the Food and Drug Administration highlighting reported poisonings and heart problems.
Trump has been heavily criticized for his handling of the virus, after initially downplaying the threat and then repeatedly rejecting scientific analysis.
The United States has by far the world’s highest coronavirus death toll, reaching 98,218 on Monday, with more than 1.6 million confirmed infections.
Despite the WHO suspension, Brazil’s health ministry said Monday it would keep recommending hydroxychloroquine for COVID-19.
“We’re remaining calm and there will be no change,” health ministry official Mayra Pinheiro told a news conference.
Bolsonaro is a staunch opponent of lockdown measures and like Trump has played down the threat of the virus, even as Latin America has emerged as the new global virus hotspot.
Brazil has reported nearly 375,000 cases, widely considered to be far fewer than the real number because of a lack of testing, and more than 23,000 deaths.
Chile also is in the grip of a virus surge, with a record of nearly 5,000 infections in 24 hours on Monday.
While South America and parts of Africa and Asia are only just beginning to feel the full force of the pandemic, many European nations are easing lockdowns as their outbreaks are brought under control.
In hard-hit Spain, Madrid and Barcelona on Monday emerged from one of the world’s strictest lockdowns, with parks and cafe terraces open for the first time in more than two months.
Elsewhere, gyms and swimming pools reopened in Germany, Iceland, Italy and Spain.
And slowing infection rates in Greece allowed restaurants to resume business a week ahead of schedule — but only for outdoor service.
“I’m thrilled to break the isolation of recent months and reconnect with friends,” said pensioner Giorgos Karavatsanis.
“The cafe in Greece has a social dimension, it’s where the heart of the district beats.”
Despite the encouraging numbers, experts have warned that the virus could hit back with a devastating second wave if governments and citizens are careless, especially in the absence of a vaccine.
The latest reminder of the threat came from Sweden, where the COVID-19 death toll crossed 4,000 — a much higher figure than its neighbors.
The Scandinavian nation has gained international attention — and criticism — for not enforcing stay-at-home measures like other European countries.
The extended lockdowns, however, have started to bite globally, with businesses and citizens wearying of confinement and suffering immense economic pain.
Unprecedented emergency stimulus measures have been introduced, as governments try to provide relief to their economies, with the airline and hospitality sectors hit particularly hard because of travel bans.
Lufthansa became the latest major global company to be rescued, as the German government agreed a 9 billion euros ($9.8 billion) bailout for one of the world’s biggest airlines.
But analysts have warned that the pandemic’s economic toll will be even more painful for countries far poorer than Western nations.
In the Maldives, a dream destination for well-heeled honeymooners, tens of thousands of impoverished foreign laborers have been left stranded, jobless and ostracized as the tiny nation shut all resorts to stop the virus.
“We need money to survive. We need our work,” said Zakir Hossain, who managed to send about 80 percent of his $180 a month wage to his wife and four children in Bangladesh before the outbreak.
“I heard that if a Bangladeshi worker dies here, they don’t send his body back and he is buried here,” he said. “I am worried what will happen if I die.”


US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

Updated 20 min 27 sec ago

US to pay over $1bn for 100m doses of J&J’s potential COVID-19 vaccine

  • The latest contract equates to roughly $10 per vaccine dose produced by J&J
  • This is J&J’s first deal to supply its investigational vaccine to a country

WASHINGTON: The United States government will pay Johnson & Johnson over $1 billion for 100 million doses of its potential coronavirus vaccine, its latest such arrangement as the race to tame the pandemic intensifies, the drugmaker said on Wednesday.
It said it would deliver the vaccine to the Biomedical Advanced Research and Development Authority (BARDA) on a not-for-profit basis to be used after approval or emergency use authorization by the US Food and Drug Administration (FDA).
J&J has already received $1 billion in funding from the US government — BARDA agreed in March to provide that money for the company to build manufacturing capacity for more than 1 billion doses of the experimental vaccine.
The latest contract equates to roughly $10 per vaccine dose produced by J&J. Including the first $1 billion deal with the USgovernment, the price would be slightly higher than the $19.50 per dose that the United States is paying for the vaccine being developed by Pfizer Inc. and German biotech BioNTech SE.
The US government may also purchase an additional 200 million doses under a subsequent agreement. J&J did not disclose that deal’s value.
J&J plans to study a one- or two-dose regimen of the vaccine in parallel later this year. A single-shot regimen could allow more people to be vaccinated with the same number of doses and would sidestep issues around getting people to come back for their second dose.
This is J&J’s first deal to supply its investigational vaccine to a country. Talks are underway with the European Union, but no deal has yet been reached.
J&J’s investigational vaccine is currently being tested on healthy volunteers in the United States and Belgium in an early-stage study.
There are currently no approved vaccines for COVID-19. More than 20 are in clinical trials.